5.36
-0.02 (-0.37%)
| 前收盘价格 | 5.38 |
| 收盘价格 | 5.39 |
| 成交量 | 6,693 |
| 平均成交量 (3个月) | 139,225 |
| 市值 | 29,444,410 |
| 价格/销量 (P/S) | 0.650 |
| 股市价格/股市净资产 (P/B) | 28.85 |
| 52周波幅 | |
| 利润日期 | 12 Aug 2025 |
| 营业毛利率 | -146.93% |
| 营业利益率 (TTM) | -557.51% |
| 稀释每股收益 (EPS TTM) | -15.27 |
| 季度收入增长率 (YOY) | -54.00% |
| 流动比率 (MRQ) | 0.100 |
| 营业现金流 (OCF TTM) | 15.96 M |
| 杠杆自由现金流 (LFCF TTM) | 42.76 M |
| 资产报酬率 (ROA TTM) | -69.26% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - General (US) | 看跌 | 混合的 |
| Drug Manufacturers - General (全球的) | 看跌 | 混合的 | |
| 股票 | Scilex Holding Company | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.88 |
|
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - General |
| 投资方式 | Small Value |
| 内部持股比例 | 22.38% |
| 机构持股比例 | 18.64% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| E Fund Management Co., Ltd. | 31 Mar 2025 | 31,431 |
| Rafferty Asset Management, Llc | 31 Mar 2025 | 17,717 |
| Klp Kapitalforvaltning As | 31 Mar 2025 | 10,212 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合